Riskpilot← Back to searchSign inGet full accessPharmaFocus AB
ABActiveOrg 5566316146Granvägen 9Research and experimental development on natural sciences and engineering · NACE 7210Est. 20021 employees
Revenue 2024
SEK 1,6M
+1% vs 2023
EBITDA margin
25.9%
+8% vs 2023
Equity ratio
63.9%
Financial strength
Net profit 2024
SEK 453K
+48% vs 2023
| Revenue | SEK 1,6M | +1% |
| EBITDA | SEK 415K | +8% |
| Net profit | SEK 453K | +48% |
| Total assets | SEK 2,4M | +4% |
| Equity | SEK 1,6M | +13% |
| Employees | 1 | — |
Legal name
PharmaFocus AB
Org number
5566316146
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 september 2002
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsultverksamhet inom läkemedelsbranschen med lansering, information och utbildning ävensom idka därmed förenlig verksamhet.
Address
Granvägen 9
Phone
+46733911914
Email
carinfrojd@live.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 1 453 | 1 462 | 1 431 | 1 457 | 1 475 | 1 586 | 1 602 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 353 | 493 | 427 | 467 | 406 | 376 | 406 | 325 | 383 | 415 |
| Depreciation & amort. | −81 | −81 | −81 | −70 | −70 | −70 | −70 | −70 | −0 | −0 |
| EBIT | 272 | 412 | 346 | 397 | 336 | 306 | 336 | 255 | 383 | 415 |
| Net financials | 4 | 7 | −1 | — | — | — | 12 | 15 | 26 | 41 |
| Profit before tax | 233 | 421 | 349 | 353 | 340 | 359 | 325 | 339 | 394 | 581 |
| Tax | −57 | −95 | −84 | −83 | −77 | −85 | −72 | −70 | −88 | −128 |
| Net profit | 176 | 326 | 265 | 270 | 263 | 274 | 253 | 269 | 306 | 453 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 005 | 2 178 | 2 207 | 2 368 | 2 340 | 2 290 | 2 360 | 2 339 | 2 358 | 2 445 |
| Equity | 998 | 1 110 | 1 165 | 1 205 | 1 253 | 1 287 | 1 290 | 1 319 | 1 385 | 1 563 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 221 | 285 | 263 | 340 | 269 | 237 | 280 | 301 | 238 | 273 |
| Total debt | 221 | 285 | 263 | 340 | 269 | 237 | 280 | 301 | 238 | 273 |
EBITDA margin
25.9%
This company
15.8%
Market median
+64% vs market
20152024
Equity ratio
63.9%
This company
38.2%
Market median
+67% vs market
20152024
Return on equity
29.0%
This company
18.4%
Market median
+58% vs market
20152024
Net profit margin
28.3%
This company
8.1%
Market median
+249% vs market
20152024
Asset turnover
0.66×
This company
1.12×
Market median
-41% vs market
20152024
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CD Chief Auditor | Chief Auditor | 2022 | — | — |
AC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PharmaFocus AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Daniel Larsson | Chief Auditor | 0 companies |
| Anna Carin Maria Fröjd | Chief Executive Officer | 0 companies |
| Hans Thomas Jiborn | Deputy Board Member | 0 companies |